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ABSTRACT28
Supplementary fat positively influences reproductive performance in dairy cattle,29
although the mechanisms involved are not clearly defined. Our objective was to30
determine the effects of four different fat supplements on follicle development,31
plasma steroid hormone concentrations and prostaglandin (PG) synthesis in lactating32
dairy cattle. Forty-eight early lactation Holstein-Friesian cows (21 primiparous, 2733
multiparous) were used in a completely randomised block design. Cows were fed the34
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same basal TMR diet and received one of four fat supplements: (i) palmitic acid (18:035
fatty acid; Control), (ii) flaxseed (rich in 18:3 n-3 fatty acid; Flax), (iii) conjugated36
linoleic acid (a mixture of cis-9, trans-11 and trans-10, cis-12 isomers; CLA), and (iv)37
fish oil (rich in 20:5 and 22:6 n-3 fatty acids; FO). All lipid supplements were38
formulated to be isolipidic; palmitic acid was added as necessary to provide a total39
lipid supplement intake of 500 g/d. Cows were synchronised to be in oestrus on day40
15 of dietary treatment. All antral follicles were counted, and dominant follicles,41
subordinate follicles and corpora lutea were measured daily via transrectal ovarian42
ultrasonography for one complete oestrous cycle. Blood samples were collected daily,43
and selected samples were analysed for progesterone, oestradiol, insulin-like growth44
factor-1, insulin, cholesterol and non-esterified fatty acids. Oestrus was synchronised45
a second time, and liver and endometrial biopsies were collected on day 7 of the46
oestrous cycle. Gene expression was evaluated for a number of genes involved in47
prostaglandin synthesis (endometrium) and fatty acid uptake and utilisation (liver).48
Fat supplementation had little effect on follicle development. Cows receiving49
supplementary n-3 fatty acids had lesser plasma progesterone (P4) and smaller50
corpora lutea than cows receiving the CLA or Control supplements. Effects of fat51
supplementation on the endometrial expression of genes involved in PG synthesis52
were minor. Hepatic expression of SREBF1, ASCL1 and FABP1 was reduced by FO53
supplementation. Reduced plasma P4 in n-3 supplemented cows may lead to a54
suboptimal uterine environment for embryo development and hence reduced fertility55
compared to cows receiving the control or CLA supplements.56
57
KEYWORDS: Fatty acids, reproduction, dairy cattle, progesterone.58
59
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1. INTRODUCTION60
Dairy cow diets are supplemented with fat primarily to increase the energy density of61
the diet to enhance milk production, growth and reproduction. It was initially thought62
that feeding energy dense fat supplements in early lactation, when the dairy cow is63
experiencing a period of negative energy balance, would improve the energy status of64
the animal and consequently improve reproductive performance. When fat is fed in65
early lactation, however, cows either consume less feed or increase milk production66
and energy status is seldom altered [1,2]. It has since been suggested that any benefits67
of feeding fat may be independent of energy status, and may instead be due to specific68
effects on the pituitary gland, ovaries and uterus, mediated by the fatty acid69
composition of the fat source [3]. Potential improvements in dairy cow fertility with70
supplemental fat have generally been associated with increased dominant follicle71
diameter, improved oocyte and embryo quality, greater progesterone (P4)72
concentrations, and modulation of prostaglandin (PG) synthesis, collectively resulting73
in increased likelihood of conception [4,5,6].74
Trans-10, cis-12 CLA, an n-6 polyunsaturated fatty acid (PUFA), is a potent inhibitor75
of milk fat synthesis, and has recently been demonstrated to decrease milk energy76
output, with subsequent improvements in energy balance and body condition score77
[7]. These improvements in energy balance have been shown to have a beneficial78
effect on reproductive performance [8]. Other potential mechanisms by which CLA79
might improve reproductive performance are yet to be fully elucidated.80
Flaxseed oil is high in the essential n-3 PUFA α-linolenic acid, and has been shown to81
increase the size of the dominant follicle and reduce pregnancy losses [9]. Fish oil82
contains substantial amounts of the long chain n-3 PUFAs, eicosapentaenoic acid83
(EPA) and docosahexaenoic acid (DHA). Recent studies have highlighted the84
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potential to manipulate PG synthesis by adding n-3 PUFA supplements to the diet.85
Increasing the proportion of n-3 PUFA in the diet can result in increased synthesis of86
the less biologically active 3-series PGs at the expense of PGF2α [10,11]. Studies87
conducted in vitro [12], and in vivo using beef heifers [13] demonstrated that n-388
PUFA supplementation can alter endometrial expression of genes regulating PGF2α89
synthesis, potentially leading to a reduction in uterine PGF2α production. Inhibition of90
uterine PGF2α secretion may delay the regression of the corpus luteum (CL), and91
hence improve embryo survival.92
The present study was conducted to determine the effects of four different fat93
supplements on follicle and CL development, steroid hormone concentrations and94
endometrial and hepatic gene expression in lactating dairy cows.95
96
2. MATERIALS AND METHODS97
2.1. Animals and treatments98
All experimental procedures involving animals were licensed by the Department of99
Health and Children, Ireland, in accordance with the Cruelty to Animals Act (1876)100
and the European Community Directive 86/609/EEC. Twenty one primiparous and 27101
multiparous Holstein-Friesian cows were blocked on the basis of parity, calving date,102
average daily milk yield and body condition score (BCS), and randomly assigned to103
one of four dietary fat supplements at 38 days in milk (DIM) (+/- 11 days (S.D)): 500104
g palmitic acid (Palmit 80, Trouw Nutrition, Belfast, UK) (Control); 200 g pure105
pressed flax seed (Flax 30, Bob Allen Feeds, Bandon, Ireland) containing 72 g α-106
linolenic acid (Flax); 100 g lipid-encapsulated conjugated linoleic acid (CLA) (Lutrell107
Pure, BASF, Ludwigshafen, Germany) containing 10 g each of trans-10, cis-12 CLA108
and cis-9, trans-11 CLA (CLA); or 300 g of a partially rumen protected fish oil109
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supplement (Trouw Nutrition, Belfast, UK) containing 30 g each of EPA and DHA110
(FO). All diets were balanced with Palmit 80 so that each treatment provided 500 g of111
lipid per cow per day, and manually mixed with 1.5 kg of a specially formulated112
concentrate to ensure palatability. This ration was fed in individual feed troughs and113
consumed in a single meal following the morning milking.114
The cows were housed in a free-stall barn from parturition until the end of the 70-day115
treatment period, with the treatment groups sharing common accommodation space.116
Individual dry matter intake (DMI) was measured daily throughout the trial using the117
Griffith Elder Mealmaster feeding system (Griffith Elder Ltd, Suffolk, UK). Forage118
mangers were mounted on electronic weighing scales, and cows had ad-libitum access119
to the TMR, which was offered to allow for feed refusals of 5%. Refusals were120
removed daily. Weekly samples of all feeds offered were dried and ground and121
composited on a fortnightly basis for nutrient analysis. The dry matter, ash, crude122
protein, neutral detergent fibre and oil content of the feeds were determined as123
described by McNamara et al. [14]. The ingredient and nutrient composition of the124
TMR and concentrate ration are reported in Table 1. Samples of the four fat125
supplements used in the study were also collected and fatty acid content determined126
by gas liquid chromatography, as described by Childs et al. [15] following lipid127
extraction using a chloroform/methanol/water mixture [16], and methylation using128
NaOCH3/methanol and BF3/methanol [17]. The fatty acid composition of the129
supplements offered is shown in Table 2.130
Cows were milked twice daily at 0730 and 1500, and milk yield (kg) was recorded131
daily at the morning and evening milkings using electronic milk meters (Dairy132
Master, Causeway, Co. Kerry, Ireland). Milk composition (fat, protein and lactose)133
was determined on two days per week from successive evening and morning milk134
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samples using a Milkoscan 605 (Foss Electric, Hillerod, Denmark). The following135
equation was used to calculate solids corrected milk yield (SCM) [18]:136
SCM = (12.3*milk fat yield + (6.56*(milk protein yield + milk lactose yield))-137
(0.0752*milk yield)138
Body condition score was recorded every two weeks using a 1 to 5 scale139
(1 = emaciated, 5 = extremely fat) with 0.25 increments [19]. Energy balance (EBAL)140
was estimated as the difference between energy intake and the sum of energy141
requirements for maintenance and milk production, using the French net energy142
system [20]. This system uses unité fourragère lait (UFL) as the unit of net energy,143
which is equivalent to 1 kg of standard air-dried barley. The following equations were144
used to determine the energy required for maintenance and output in milk [21]:145
Energy required for maintenance (UFL/d) =1.4+0.6×BW/100;146
Energy requirement for milk (UFL/kg of milk) = 0.0054 × FC + 0.0031 × PC +147
0.0028 × LC-0.015; where FC = fat concentration (%), PC = protein concentration148
(%), and LC = lactose concentration (%).149
Of the 48 cows on the trial, 9 cows failed to respond to synchrony treatment, and a150
further 5 cows did not ovulate at the subsequent spontaneous oestrus. In addition, two151
cows were removed from the study due to illnesses unrelated to the experimental152
treatments.153
154
2.2. Synchronisation of the oestrous cycle155
A protocol to synchronise oestrus was initiated on day 5 of dietary treatment with156
injection (i.m.) of GnRH (0.01 mg Buserelin (Receptal); Intervet, Dublin) and157
insertion of an intravaginal progesterone releasing device (Eazi-breed CIDR158
containing 1.38g P4, Pfizer Animal Health, Dublin, Ireland). On day 12 of dietary159
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treatment each cow received an injection (i.m.) of PGF2α (Lutylase, Pfizer Animal160
Health), and the following day the CIDR was removed. All cows had tail paint161
applied at CIDR removal, and were observed for oestrus over the next 5 days. The162
schedule of all experimental procedures performed is presented in Table 3.163
164
2.3. Monitoring ovarian activity165
Follicles were counted and measured, and corpora lutea measured for each cow via166
daily transrectal ovarian ultrasonography (Aloka SSD-900, Aloka Ltd, Tokyo, Japan,167
7.5 MHz transducer) from the day after CIDR removal until ovulation following the168
next spontaneous oestrus. In order to measure follicles and corpora lutea, images were169
frozen on screen during ultrasonography, and dimensions were measured with internal170
callipers on the Aloka SSD-990. The position of each large (≥10 mm diameter)171
follicle on the ovary was mapped daily to facilitate identification of the dominant172
follicle in each wave of follicular growth. Corpora lutea dimensions were recorded173
and used to calculate the average diameter and radius. Corpus luteum volume (V) was174
then calculated with the formula V = 4/3x π x radius3. For CL with a fluid-filled175
lacuna the volume of the lacuna was calculated and subtracted from the total volume176
of the CL.177
178
2.4. Blood sampling and hormone and metabolite analysis179
Blood samples were collected from each cow after the morning milking on the day of180
initiation of dietary treatment, on day 7 of dietary treatment, on the day after CIDR181
removal, and daily thereafter until the day of ovulation at the spontaneous oestrus182
following the synchronised oestrus. Blood samples were collected from the coccygeal183
vessels into lithium heparin vacutainers. Following collection, all blood samples were184
REVISED
9
centrifuged at 2000 x g for 15 min at 5 °C. The plasma was harvested and decanted185
into 1.5 mL tubes, sealed with an airtight cap and stored at -20 °C until further186
analysis.187
All blood samples collected were analysed for plasma P4 concentration, and samples188
from days 0, 15, 25 and 35 of dietary treatment were analysed for insulin-like growth189
factor-1 (IGF-1), insulin, cholesterol and non-esterified fatty acid (NEFA)190
concentrations. Ultrasonography and heat detection records were used to select the191
blood samples analysed for oestradiol (E2) concentrations. Three consecutive samples192
from the day prior to synchronised oestrus, and 7 consecutive samples from 5 days193
prior to spontaneous oestrus were analysed for E2 concentration.194
Plasma P4 and insulin concentrations were determined using solid-phase fluoro-195
immunoassays (AutoDELFIA, PerkinElmer Life and Analytical Sciences, Turku,196
Finland), with appropriate kits (Unitech BD Ltd., Dublin, Ireland). Plasma IGF-I197
concentrations were quantified by radioimmunoassay, following198
ethanol:acetone:acetic acid extraction as described by Butler et al. [22]. Plasma E2199
concentrations were determined as described by [23], using an E2 MAIA assay kit200
(Biostat Ltd, Stockport, UK). All hormone assays included a high, medium and low201
control, each treatment was equally represented in each assay, and all samples for a202
cow on a given treatment were completed in a single assay. Inter-assay coefficients of203
variation (CV) for P4 were 2.5% (high), 10.4% (medium) and 20.8% (low), and intra-204
assay CV for P4 were 7.0% (high), 8.3% (medium), 21.8% (low). Inter-assay CV for205
insulin were 7.9% (high), 13.1% (medium) and 21.3% (low), and intra-assay CV for206
insulin were 10.9% (high), 12.5% (medium) and 15.9% (low). Inter-assay CV for207
IGF-1 were 8.2% (high), 2.2% (medium) and 11.9% (low), and intra-assay CV for208
IGF-I were 9.7%, (high), 9.5% (medium) and 11.4% (low). Inter-assay CV for E2209
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were 12.7% (high), 9.8% (medium) and 25.7% (low), and intra-assay CV for E2 were210
8.0 % (high), 8.9 % (medium) and 38.2 % (low). Plasma cholesterol and NEFA211
concentrations were determined by enzymatic colorimetry using appropriate kits212
(cholesterol kit supplied by Horiba ABX, Montpellier, France, NEFA kit supplied by213
Wako Chemicals, GmbH, Nissanstrase, Germany).214
215
2.5. Tissue biopsies216
Following the synchronised cycle when cows were scanned daily, the cows were217
given a 10-day period of rest. The cows were then re-synchronised with two injections218
(i.m.) of PGF2α (Lutylase, Pfizer Animal Health) after consecutive morning and219
evening milkings. Tail paint was applied to aid heat detection, and transrectal220
ultrasonography was used following observed oestrus to confirm ovulation. Liver and221
endometrial biopsies were collected 7 days after ovulation to examine gene expression222
at this stage of the oestrous cycle.223
For the liver biopsy, a site between the 11th and 12th ribs was shaved, sanitised with224
Videne (Povidone-iodine, 7.5%; Ecolab, Leeds,UK) and methylated spirits, and225
anaesthetised with Willcain (Dechra Ltd, Shrewsbury, UK). An incision of226
approximately 1 cm was made through the skin and the biopsy instrument was used to227
pierce the intercostal muscles and peritoneum. The liver was located and a 1 to 1.5 g228
sample removed. The sample was immediately washed in saline, blotted dry, snap229
frozen in liquid nitrogen and stored at -80 °C. The incision site was sutured and230
treated topically with Duphacycline spray (Interchem, Naas, Ireland) and cows were231
given 10 mL of a subcutaneous antibiotic as a prophylactic (Excenel RTU, Pfizer232
Animal Health). For the endometrial biopsy, animals were given caudal epidural233
anaesthesia with Willcain, the external genital area was sanitized, and a biopsy tool234
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passed through the cervix and into the uterine horn ipsilateral to the CL by using235
transrectal manipulation. The open jaws of the biopsy basket (2 × 1 mm) were pressed236
against the endometrium and samples (approximately 100 mg) of endometrium237
removed. The samples were then washed in saline, blotted dry, snap frozen in liquid238
nitrogen, and stored at −80 °C. Animals were given 500 mg of an intrauterine239
prophylactic antibiotic (Metricure, Intervet, Bray, Co Wicklow, Ireland).240
241
2.6. RNA extraction and cDNA synthesis242
Total RNA was isolated from frozen tissue using TRI® Reagent and chloroform243
(Sigma-Aldrich Ireland Ltd. Dublin, Ireland). Homogenisation of the sample in TRI®244
Reagent was performed using a tissue lyser (Qiagen Ltd., Crawley, UK) and the RNA245
was subsequently extracted using chloroform and precipitated using isopropanol.246
Quantity and quality of total RNA was assessed using the NanoDrop ND-1000247
spectrophotometer (NanoDrop Technologies, DE, USA) and the Agilent Bioanalyser248
2100 with the RNA 6000 Nano Lab Chip kit (Agilent Technologies Ireland Ltd.249
Dublin, Ireland), respectively. RNA quality was verified by ensuring all RNA samples250
had an absorbance (A260/280) of between 1.8 and 2 and RINs of between 7 and 10.251
RNA samples were treated with RQ1 RNase-free DNase (Promega UK Ltd.,252
Southampton, UK) and purified using the RNeasy1 mini kit (Qiagen Ltd.). DNase-253
treated and purified total RNA was then reverse transcribed to cDNA, with random254
hexamers, using the High Capacity cDNA Reverse Transcription kit (Applied255
Biosciences, Ireland) according to the manufacturers instructions and stored at -20 °C256
for subsequent analyses.257
258
2.7. Primer design and reference gene selection259
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All candidate and reference gene primers used to detect endometrial and hepatic gene260
expression (Table 4) in this study were designed using the Primer3 web based261
software program (http://frodo.wi.mit.edu/primer3/) [24], and obtained from a262
commercial supplier (Sigma Aldrich Ltd., Dublin, Ireland). Primer specificity was263
checked using the Basic Local Alignment Search Tool (BLAST) from the National264
Center for Biotechnology Information (http://www.ncbi.nlm.nih.gov/BLAST/). All265
the primers were validated using a pooled cDNA sample. A standard curve was266
generated using serial dilutions of pooled cDNA. PCR products generated by267
amplification were sequenced to verify their primer specific identity (Biochemistry268
DNA Sequencing Facility, University of Cambridge). To determine the relative gene269
expression levels, suitable highly stable reference genes were required. In the current270
study, out of five tested, three reference genes for both endometrial (beta-actin271
(ACTB), ubiquitin (UBQ) and ribosomal protein S9 (RPS9)) and hepatic tissue272
(adenylate cyclase-associated protein (CAP1), proteasome 26S subunit, non-ATPase273
(PSMD) and ACTB were used to normalise gene expression data. The principle behind274
the selection of the reference gene is that the expression ratio of two perfect reference275
genes should be constant across all samples. The expression stability of the reference276
genes was validated with the software program, geNorm version 3.5, by calculating277
the gene expression stability measure (M value). Using three reference genes, the M278
values were 0.56 (ACTB, UBQ, RPS9) and 0.37 (ACTB, PDSM2, CAP1) for279
endometrial and hepatic RNA samples, respectively, both of which were below the280
default minimum coefficient of 1.5 as specified by the geNorm program [25].281
282
2.8. Quantitative real time PCR (qPCR)283
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Following reverse transcription, cDNA quantity was determined and standardised to284
the required concentration for qPCR. Triplicate 20 μL reactions were carried out in285
96-well optical reaction plates (Applied Biosystems, Warrington, UK), containing 1286
μL cDNA (10-50 ng of RNA equivalents), 10 μL Power SYBR® Green PCR Master287
Mix (Applied Biosystems), 8 μL nuclease-free H2O, and 1 μL forward and reverse288
primers (250-1000 nM per primer). Assays were performed using the ABI 7500 Fast289
qPCR System (Applied Biosystems) with the following cycling parameters: 95 C for290
20 s and 40 cycles of 95 C for 30 s, 60 C for 30 s followed by amplicon dissociation291
(95 C for 15 s, 60 C for 1 min, 95 C for 15 s and 60 C for 15 s). Gene expression292
levels were recorded as Ct values, i.e. the number of PCR cycles at which the293
fluorescence signal is detected above the threshold value and all samples were run in294
triplicate. Amplification efficiencies were determined for all candidate and reference295
genes using the formula E=10^(−1/slope), with the slope of the linear curve of cycle296
threshold (Ct) values plotted against the log dilution [26]. Primer concentrations were297
optimized for each gene and disassociation curves were examined for the presence of298
a single PCR product. The efficiency of the reaction was calculated using a 5-fold299
serial dilution of cDNA and generation of a standard curve. All PCR efficiency300
coefficients were between 0.9 and 1.1 and therefore deemed acceptable. The software301
package GenEx 5.2.1.3 (MultiD Analyses AB, Gothenburg, Sweden) was used for302
efficiency correction of the raw Ct values, interplate calibration based on a calibrator303
sample included on all plates, averaging of replicates, normalization to the reference304
gene and the calculation of quantities relative to the highest Ct and log2305
transformation of the expression values for all genes.306
307
2.9. Statistical analysis308
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All statistical analyses were carried out using SAS (SAS System Inc., Cary NC,309
USA). Daily measurements of milk yield, DMI and EBAL were collapsed into weekly310
means. A test for normality was performed on all the blood analyte data using the311
UNIVARIATE procedure of SAS. Insulin, IGF-1 and NEFA variables were log-312
transformed prior to analysis to generate a normal distribution. Milk production, milk313
composition, DMI, BCS, EBAL, blood analyte and CL volume data were analysed314
using mixed models with repeated measures, using the satterthwaite adjustment to315
calculate denominator degrees of freedom. The appropriate covariance structure for316
each repeated measures analysis was identified based on Akaike’s Information317
Criterion (AIC) model fit statistic. Where appropriate, measurements made during the318
3 wk prior to the initiation of dietary treatment were included as covariates in the319
models for milk yield and composition, IGF-I, insulin, NEFA, cholesterol, DMI, BCS320
and calculated EBAL. Parity and calving date were included as adjustment variables321
in all repeated measures models; if non-significant, these variables were removed and322
the models were re-run. Follicle development, peak plasma E2 concentrations at323
oestrus, and day of luteolysis data were analysed using mixed models procedures with324
treatment as a fixed effect, block as a random effect, and calving date and parity325
included as adjustment variables.326
Day of luteolysis was defined as the day before plasma P4 declined to less than 50%327
of the average for the four maximum P4 concentrations in the cycle. Additionally,328
plasma P4 must have declined again to less than 25% of the 4 maximum average P4329
concentrations the following day [27]. Individual cows began undergoing luteolysis330
from day 14 after ovulation onwards; therefore P4 and CL volume data after day 14331
were not included in the statistical analysis. Further specific analysis of plasma P4332
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concentration and CL volume was performed on data from days 5-7 after ovulation333
and from days 8-14 after ovulation.334
All gene expression data was tested for normality using the UNIVARIATE procedure335
of SAS. A Box-Cox transformation analysis was performed using the TRANSREG336
procedure in SAS to obtain the appropriate lambda value for data that were not337
normally distributed. These data were then transformed by raising the variable to the338
power of lambda. Mixed models (PROC MIXED) were used to determine the effect339
of fat supplementation on the relative expression of each gene measured. The Tukey340
critical difference test was used to determine statistical differences between treatment341
means. In all statistical analyses, contrast statements were used to compare individual342
fat treatments against one another, and also to compare the two n-3 supplements343
combined (Flax and FO) against both Control and CLA supplements. Data were344
considered significant when P<0.05, and a trend declared when P<0.1.345
346
3. RESULTS347
3.1. Milk production, dry matter intake, body condition score and energy balance348
Milk production, DMI, BCS and EBAL data are summarised in Table 5. Milk yield349
was greater for CLA-supplemented cows compared with all other treatments (P =350
0.007); the remaining treatments did not differ from each other. There was a351
significant effect of treatment on milk fat concentration and yield (both P < 0.001).352
CLA supplementation reduced milk fat concentration and yield compared with all353
other treatments, and FO cows had reduced milk fat concentration and yield compared354
with those on the Control and Flax diets. Milk protein concentration was reduced for355
CLA-supplemented cows compared with cows receiving Control and Flax treatments356
(P = 0.018). Milk protein yield was reduced for FO-treated cows compared with both357
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Flax and CLA-supplemented cows, and was greater for Flax-treated cows compared358
with cows receiving the Control diet (P = 0.03). Milk lactose concentration was359
increased for cows receiving FO compared with those receiving the Control and CLA360
treatments, and cows receiving the Flax supplement had elevated milk lactose361
concentrations compared with cows on the CLA diet (P = 0.008). Overall, solids-362
corrected milk yield (SCM) was increased for cows on the Control and Flax diets363
compared with cows on the CLA and FO diets (P < 0.001). There was no effect of364
treatment on DMI, EBAL or BCS.365
366
3.2. Ovarian follicular dynamics and peak oestradiol concentrations367
Follicle development is summarised in Table 6. The type of fat supplement tended to368
affect both the length of the oestrous cycle and the number of follicles in the first369
wave of the cycle (P = 0.09 and 0.07, respectively). The oestrous cycle of cows370
receiving the Flax supplement was 3.5 d shorter than for the Control group (P = 0.04),371
and 4.6 d shorter compared with cows offered the FO supplement (P = 0.02). The FO-372
supplemented cows had 2.2 fewer follicles in the first wave of the cycle compared373
with those fed the Control supplement (P = 0.01). Peak plasma E2 at the synchronised374
oestrus was 1.62 pg/mL greater (P = 0.046) in Flax-supplemented cows compared375
with FO-supplemented cows, and tended to be 1.32 pg/mL greater (P = 0.08) in Flax-376
supplemented cows compared with cows receiving the Control supplement. Peak377
plasma E2 at the spontaneous oestrus tended to be 0.85 pg/mL greater (P = 0.09) in378
Flax-supplemented cows compared with cows receiving the Control supplement.379
There was no overall treatment effect on the day of first wave peak follicle diameter,380
but peak follicle diameter in the first follicular wave occurred 1.5 days earlier after381
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ovulation in Control cows compared with cows receiving the FO diet (P = 0.04). No382
other follicle or E2 variables were affected by the type of fat supplement.383
384
3.3. Plasma progesterone concentrations and corpus luteum volumes385
The effect of fat supplementation on plasma P4 and CL volume is shown in Table 7.386
and Figure 1.387
Days 2-14 after ovulation: There was a significant effect of treatment on both plasma388
P4 concentration and CL volume from days 2 – 14 of the oestrous cycle (P = 0.013389
and 0.04 respectively). Mean plasma P4 concentrations were 0.62 ng/mL (P = 0.04)390
and 0.87 ng/mL (P = 0.001) less for cows receiving the Flax supplement compared391
with cows receiving the Control and CLA supplements, respectively. Mean plasma P4392
concentrations in cows on the FO diet were 0.67 ng/mL (P = 0.03) and 0.92 ng/mL (P393
= 0.01) less compared with cows receiving the Control and CLA supplements,394
respectively. Corpus luteum volumes were 1464 mm3 less (P = 0.03) and 2077 mm3395
less (P = 0.005) for FO-treated cows compared with cows receiving the Control and396
CLA supplement, respectively. The n-3-supplemented cows had lesser plasma P4397
compared with Control (4.48 ng/mL vs. 5.13 ng/mL, P = 0.01) and CLA-398
supplemented cows (4.48 ng/mL vs. 5.38 ng/mL, P = 0.004). Corpus luteum volumes399
were lesser in n-3-supplemented cows compared with CLA-supplemented cows (6355400
mm3 vs. 7965 mm3, P = 0.01). There was a tendency for primiparous animals to have401
smaller CL volumes than mulitparous cows (6380 mm3 vs. 7632 mm3, P = 0.06).402
There was no effect of treatment on the number of days from ovulation to luteolysis.403
Days 5-7 after ovulation: There was no overall treatment effect on either plasma P4404
or CL volumes; however, CLA-treated cows had 1.17 ng/mL greater plasma P4405
concentrations (P = 0.04) and 2507 mm3 larger CL volumes compared with cows406
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receiving the FO diet (P = 0.03). The n-3-supplemented cows had reduced plasma P4407
concentrations (3.32 ng/mL vs. 4.24 ng/mL, P = 0.04) and CL volumes (6249.7 mm3408
vs. 8125.7 mm3, P = 0.04) compared with the CLA-supplemented cows.409
Days 8-14 after ovulation: There was a significant effect of treatment on plasma P4410
from days 8-14 after ovulation. Mean plasma P4 concentrations in CLA treated cows411
were 1.20 ng/mL greater (P = 0.006) and 1.28 ng/mL greater (P = 0.007) compared412
with cows receiving the Flax and FO supplements, respectively. The n-3-treated cows413
had lesser mean plasma P4 concentrations compared with both the Control (6.50414
ng/mL vs. 7.20 ng/mL, P = 0.04) and CLA-supplemented (6.50 ng/mL vs. 7.74415
ng/mL, P = 0.002) cows. There was no overall treatment effect on CL volume on days416
8-14 after ovulation, but both CLA-treated (9668.8 mm3 vs. 7353.7 mm3, P = 0.04)417
and Control (9490.2 mm3 vs. 7353.7 mm3, P = 0.05) cows had larger CL compared418
with cows receiving the FO diet.419
420
3.4. Metabolites and metabolic hormones421
Mean IGF-1, insulin, cholesterol and NEFA concentrations on days 15, 25 and 35 of422
dietary treatment are presented in Table 7. The type of fat supplement tended to affect423
plasma insulin (P = 0.09) and IGF-1 (P = 0.07) concentrations. Plasma insulin424
concentrations were 0.94 µUI/mL greater (P = 0.02) in Control-treated cows425
compared with cows receiving the FO supplement. Plasma IGF-1 concentrations were426
15.7 ng/mL greater (P = 0.008) for cows receiving the Flax diet compared with cows427
receiving the Control diet. The n-3-supplemented cows had greater plasma IGF-1428
concentrations compared with cows receiving the Control diet (84.6 ng/mL vs. 73.4429
ng/mL, P = 0.03)430
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There was a significant effect of treatment on plasma cholesterol concentrations (P =431
0.02). Plasma cholesterol concentrations in CLA-supplemented cows were 0.97432
mmol/L greater (P = 0.002) and 0.75 mmol/L greater (P = 0.01) compared with cows433
receiving the Control and FO supplements, respectively. The CLA-supplemented434
cows had greater plasma cholesterol concentrations compared with cows receiving the435
n-3 supplements (5.94 mmol/L vs. 5.32 mmol/L, P = 0.02).436
There was a significant effect of treatment on plasma NEFA concentrations (P =437
0.01). Cows receiving the Control supplement had 0.05 mmol/L less (P = 0.03), 0.07438
mmol/L less (P = 0.007), and 0.08 mmol/L less (P = 0.003) plasma NEFA439
concentrations compared with cows receiving the Flax, CLA and FO supplements,440
respectively. Plasma NEFA concentrations were greater in n-3-treated cows compared441
with cows receiving the Control supplement (0.23 mmol/L vs. 0.16 mmol/L, P =442
0.003).443
444
3.5. Endometrial gene expression445
Endometrial gene expression data are presented in Table 8. There was a significant446
effect of treatment on PPARγ expression (P = 0.015). Endometrial PPARγ expression447
was increased 1.9 fold (P = 0.005) and 1.5 fold (P = 0.05) in cows receivng the FO448
diet compared with cows offered the Control and CLA diets, respectively. Flax-449
treated cows had 1.7 fold greater PPARγ expression compared with Control-treated450
cows (P = 0.008). The mRNA abundance of PPARγ was increased 1.8 fold (P =451
0.002) and 1.4 fold (P = 0.03) for n-3-treated cows compared with cows receiving the452
Control and CLA diets, respectively. Fat supplementation tended to affect both453
PPARδ and PTGS2 expression (P = 0.09 and 0.08 respectively). Endometrial PPARδ454
expression was 2.0 fold greater for cows receiving the Flax treatment compared with455
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those receiving the Control supplement (P = 0.02). When the two n-3 treatments were456
combined, PPARδ expression was 2.0 fold greater (P = 0.02) compared with cows457
receiving the Control diet. Endometrial PTGS2 expression was 2.6 fold (P = 0.01) and458
2.4 fold greater (P = 0.04) for Flax-treated cows compared with Control and FO-459
supplemented cows, respectively. Although there was no overall treatment effect on460
endometrial PGFS2 expression, a 2.1 fold increase (P = 0.04) in PGFS2 expression461
for n-3-supplemented cows compared with Control cows was observed. There was no462
overall treatment effect on endometrial PLA2 expression, but cows receiving the Flax463
treatment tended to have a 2.0 fold increase (P = 0.07) in endometrial PLA2464
expression compared with Control-supplemented cows. There was no effect of465
treatment on endometrial expression of PPARα, OTR, PGFS1, PGES, CBR1 or466
FADS2.467
468
3.6. Hepatic gene expression469
Hepatic gene expression data are presented in Table 8. There was a significant effect470
of treatment on hepatic ACSL1, FABP1 and SREBF1 expression. Hepatic expression471
of ACSL1 was increased for cows on Control (2.2 fold, P = 0.002), Flax (2.2 fold, P =472
0.002) and CLA (2.3 fold, P = 0.001) treatments compared with cows receiving the473
FO treatment. Hepatic expression of FABP1 was increased in cows on the Flax (3.7474
fold, P < 0.001), Control (3.0 fold, P = 0.005) and CLA (3.0 fold, P = 0.006)475
treatments compared with cows on the FO treatment. Hepatic expression of SREBF1476
was increased in cows on the Control (3.5 fold, P = 0.003), Flax (2.8 fold, P = 0.014)477
and CLA (3.6 fold, P = 0.002) treatments compared with cows on the FO treatment.478
There was no effect of fat supplementation on hepatic expression of ACADVL,479
ACOX1, CPT1A, DGAT1, GPAM, SCAP, SLC27A1, PPARα, CYP3A, or CYP2C.480
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481
4. DISCUSSION482
483
The objective of the current study was to identify the effects of four fat supplements484
differing in fatty acid composition on follicle and CL development, steroid hormone485
concentrations and endometrial and hepatic gene expression in lactating dairy cows.486
The most important finding from this study was the differential effects of the fat487
supplements on plasma P4 concentration and CL volume.488
The central role that P4 plays in optimising the uterine microenvironment to support489
embryo development in early pregnancy is widely accepted [28]. Cows that displayed490
both a delayed rise in plasma P4 concentrations after ovulation and lower luteal phase491
plateau concentrations of plasma P4 had retarded embryo development, with little or492
no interferon-τ (IFN-τ) production on day 16 after insemination compared with cows493
that had a normal P4 profile [29]. In the current study, mean plasma P4 concentrations494
were reduced for the n-3-supplemented cows throughout the oestrous cycle. Elevated495
P4 concentrations on days 5-7 and days 8-14 after ovulation were observed in cows496
on the CLA and Control treatments compared with cows on the n-3 supplements. The497
increase in plasma P4 at critical times in the oestrous cycle could alter uterine498
endometrial secretions to stimulate embryo development, leading to a larger embryo499
capable of signalling its presence to the dam. The differences in plasma P4500
concentrations between the treatments were accompanied by similar differences in CL501
volume.502
Dietary fat supplementation has consistently increased plasma cholesterol503
concentrations [2], the precursor for P4 synthesis. However, feeding whole flaxseed504
has been reported to decrease plasma cholesterol concentrations compared to fat505
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sources low in n-3 PUFA [30,31], and incubation of dispersed luteal cells with EPA506
and DHA reduced P4 concentrations [32]. In the current study, cows on the Control507
diet had the lowest concentrations of plasma cholesterol, yet greater plasma P4508
concentrations compared with n-3-treated cows. This indicates that cholesterol509
availability was not the limiting factor in P4 synthesis, and that alternative510
mechanisms are responsible for the variations in plasma P4 concentrations observed.511
Transport of cholesterol from the cytoplasm to the inner cell membrane, mediated by512
the steroidogenic acute regulatory protein (StAR), is the rate limiting step in P4513
biosynthesis [33]. Once inside the mitochondrion, Cytochrome P450 cholesterol side514
chain cleavage enzyme (P450scc) converts cholesterol to pregnenolone, which is then515
converted to P4 by 3β-hydroxysteroid dehydrogenase/ Δ5, Δ4 isomerase (3β-HSD)516
[33]. It is possible that the dietary treatments utilised in the current study influenced517
the luteal expression and activity of one or more of the genes involved in P4518
biosynthesis.519
Following ovulation, the granulosa cells of the follicle differentiate into large luteal520
cells to form the CL, and these large luteal cells may be responsible for up to 80% of521
progesterone secretion in the mature CL [34]. It has been suggested that an increase in522
CL volume in cows supplemented with PUFA may be due to increased numbers of523
granulosa and theca cells from a larger dominant follicle [35]. The lack of treatment524
differences in ovulatory follicle diameter in the current study does not support this525
hypothesis. Treatment differences in CL volumes in the current study may be due to526
either greater numbers of granulosa cells undergoing differentiation at ovulation, or527
increased survival of these cells following formation of the CL. Further work is528
required to fully determine the mechanisms responsible for the larger CL volume529
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observed in the current study, and to determine if larger CL volume was associated530
with greater ovarian P4 secretion.531
It has been suggested that dietary fat supplementation influences metabolic clearance532
rate (MCR) of progesterone in cattle [36]. The majority of P4 is catabolised by the533
cytochrome P450 2C (CYP2C) and cytochrome P450 3A (CYP3A) enzymes in the534
liver [37]. The lack of any differences between treatments in hepatic mRNA535
expression of the P4 catabolic enzymes CYP2C and CYP3A suggests that alterations536
in P4 synthesis rather than MCR was a more important source of the variation537
observed in plasma P4 in the current study.538
Endometrial biopsies were collected on day 7 of the oestrous cycle in the current539
study. This time point was selected as it represents a critical stage in embryo540
development, when the embryo descends into the uterus [28]. A prerequisite for PG541
synthesis is the generation of the PUFA substrate within the cell (e.g., arachidonic542
acid for 2-series PGs). Arachidonic acid (AA) is liberated from the phospholipid543
membrane by the action of a phospholipase. Many phospholipases have been544
identified, of which intracellular Group IV cytosolic A2α (PLA2α) appears most545
important in controlling the availability of free AA for PG synthesis [38]. The free546
AA is then metabolized by prostaglandin G/H synthase enzymes (PTGS2) to an547
intermediate, PGH2, which is in turn converted to either PGF2 or PGE2 by the548
enzymes PGF synthase (PGFS1 and PGFS2), and PGE synthase (PGES). Additional549
PGF2α may be synthesised by the reduction of PGE2, catalysed by the Carbonyl550
Reductase enzyme CBR 1 [39]. In the current study, a tendency towards increased551
endometrial expression of PLA2α was observed for cows receiving the Flax552
supplement compared with Control animals. This may indicate increased availability553
of AA for PG synthesis, a theory supported by the concurrent increases in endometrial554
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expression of both PTGS2 and PGFS2 in cows receiving the Flax treatment compared555
with Control animals. To the authors’ knowledge, the present study is the first to556
investigate the effect of Flax supplementation on endometrial expression of genes557
involved in PG synthesis.558
Peroxisome proliferator-activated receptors (PPARα, PPARδ and PPARγ) are a 559
family of nuclear receptors that are activated by binding of natural ligands, such as560
PUFA [40]. It has been suggested that PPARδ is involved in the pregnancy561
recognition process of cattle and may mediate some of the proposed beneficial effects562
of n-3 PUFA supplementation on PG synthesis [13,41]. The findings of the current563
study do not support this hypothesis, as the increase in endometrial PPARδ expression564
with n-3 PUFA supplementation was not accompanied by suppression of genes565
involved in the synthesis of PGF2α. It is important to note, however, that in the current566
study endometrial biopsies were collected on day 7 of the oestrous cycle, some 8-10567
days prior to maternal recognition of pregnancy. This may provide some explanation568
for the contrast in results between the current study and the work of Coyne et al. [13],569
who used tissue collected after animals were slaughtered on day 17 of the oestrous570
cycle. The increase in endometrial PPARγ expression with n-3 PUFA571
supplementation in the current study are not consistent with the findings of MacLaren572
et al. [41] using cell culture, and Coyne et al. [13] using beef heifers, who found no573
effect of n-3 PUFA supplementation on endometrial PPARγ expression.574
Polyunsaturated fatty acids are known to affect the expression of genes involved in575
diverse metabolic pathways [42]. Fatty acid regulation of hepatic gene transcription is576
controlled by the transcription factors, PPARα and SREBF-1 [43]. These transcription577
factors regulate the activity of a number of genes involved in fatty acid transport578
(SLC27A1 and FABP1), triacylglycerol synthesis (DGAT1) and fatty acid oxidation579
REVISED
25
(CPT1A, ACOX1 and ASCL1) [43]. Liver biopsies were taken on day 7 of the oestrous580
cycle in the current study. Day 7 was selected as the hormonal milieu (increasing581
progesterone, low oestradiol) would have been the same in all cows at this stage of the582
cycle. Any confounding effects of steroid hormones on hepatic metabolism [44] were583
therefore negated. Hepatic expression of ASCL1, FABP1 and SREBF1 were reduced584
in FO supplemented cows compared to all other treatments. The differences in fatty585
acid composition of the FO supplement are likely to be the cause of these differences586
in hepatic gene expression. In contrast to the other three supplements, which contain587
fatty acids with 18 carbon chains or less, FO contains significant amounts of the very588
long chain PUFA, EPA and DHA. Deckelbaum et al. [45] noted that EPA, DHA and589
arachidonic acid (AA) have a greater inhibitory effect on SREBF1 expression than590
shorter chain PUFA. This inhibitory effect on SREBF1 is in turn reflected in reduced591
ACSL1 and FABP1 expression, as SREBF1 is a major modulator of these genes [45].592
The development of ovarian follicles during the early postpartum period has been593
consistently demonstrated to be stimulated by fat supplementation [2]. Few594
differential effects of fat supplementation on ovarian follicular development were595
observed in the current study, in agreement with Childs et al. [46], who found no596
differences in follicle development when supplementing heifers with either whole597
soybean (n-6) or a fish oil (n-3) supplement. Similarly, Petit and Twagiramungu [35]598
were unable to determine any differences in follicle development in cows fed either599
Megalac, an n-3 flaxseed supplement or an n-6 soybean supplement.600
Cows receiving the Flax treatment had shorter cycle lengths than cows fed either the601
Control or FO diets. As ovulatory follicle size was unaffected by treatment, it is602
plausible that a shorter oestrous cycle may have beneficial effects for subsequent603
likelihood of conception by reducing the likelihood of ovulation of follicles with604
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prolonged dominance [47,48]. Reduced E2 concentrations around the time of oestrus605
have been demonstrated to be related to decreased duration and intensity of oestrus606
behaviour in lactating dairy cows [49]. The differences in peak plasma E2 observed in607
the current study are in agreement with the work of Robinson et al. [31], who608
demonstrated increased peak plasma E2 concentrations for cows fed an n-3 flaxseed609
supplement compared with cows fed an isoenergetic control supplement. The increase610
in plasma IGF-1 concentrations in Flax supplemented cows in the current study may611
provide some explanation for the increased E2 concentrations, as plasma E2612
concentrations during pre-ovulatory follicle development have been shown to be613
highly correlated with plasma IGF-1 concentrations [50]. Our observations of614
increased plasma concentrations of IGF-1 in n-3 supplemented cows compared to615
Control animals are consistent with the work of Childs et al. [15].616
The treatment differences in plasma NEFA concentrations observed in the current617
study are most likely due to the degree of saturation of the fatty acid supplement, as618
the Control supplement was the only fully saturated fat source. The plasma NEFA619
levels observed in the current study were generally low, and as such unlikely to have620
influenced the reproductive mechanisms examined in the study.621
Trans-10, cis-12 CLA is a potent inhibitor of milk fat synthesis and has been shown to622
reduce milk energy output and improve energy balance in early lactation dairy cows623
[7]. In the present study we observed reductions in milk fat concentration and yield624
for CLA-supplemented cows compared with Control, Flax and FO-treated cows.625
There also appears to have been an inhibitory effect of the FO treatment on milk fat626
synthesis; both milk fat concentration and yield were reduced compared to Control627
and Flax treatment, although to a lesser extent than observed for CLA-treated cows.628
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The reduction in milk fat synthesis with FO supplementation is consistent with other629
reports [51,52].630
631
5. CONCLUSIONS632
The fat supplements used in the current study had diverse effects on reproductive633
parameters. Plasma P4 concentrations were increased for Control and CLA-634
supplemented cows in comparison with cows receiving n-3 PUFA supplements. The635
increase in plasma P4 concentrations in Control and CLA-supplemented cows636
occurred without any concurrent deleterious effects on either follicle development or637
gene expression related to PG synthesis. The endometrial gene expression results638
indicate that n-3 PUFA supplementation does not suppress the expression of enzymes639
involved in PGF2α synthesis on day 7 of the oestrous cycle. Compared to other fat640
sources, feeding n-3 PUFA to lactating dairy cows may have negative implications for641
embryo development, due to suppressive effects on plasma P4 concentrations.642
643
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Table 1: Ingredient and nutrient composition of the TMR and concentrate rations offered
TMR ingredients (% DM)
Grass Silage 34
Maize Silage 34
Straw 3
TMR premix 29
TMR premix ingredients (% DM)
Wheat 16
Citrus pulp 5
Barley 16
Maize gluten feed 30
Soybean meal 25
Molasses (cane) 5
Vitamins and minerals1 3
Nutrient Composition (DM basis)
DM (g/kg) 915.2
Net Energy (UFL/kg of DM) 2 0.85
Ash (g/kg of DM) 57.3
CP (g/kg of DM) 162.2
NDF (g/kg of DM) 410.0
Oil (acid hydrolysis; %) 2.5
Balancer Ration Composition (% as fed)
Wheat 20
Citrus Pulp 15
Barley 15
Maize Gluten Feed 35
Soybean meal 10
Molasses (cane) 5
Treatment
Total Concentrate Ration Composition (kg as fed) Control Flax CLA FO
Balancer Ration 1.5 1.5 1.5 1.5
Palmit 80 0.5 0.43 0.4 0.35
Flax 30 - 0.2 - -
LE-CLA - - 0.1 -
Fish oil supplement - - - 0.3
Total supplemental lipid fed per day 0.5 0.5 0.5 0.5
Total ration fed per day 2.0 2.13 2.0 2.15
Nutrient Composition (DM basis)
DM (g/kg) 941.1 942.9 944.6 945.4
CP (g/kg of DM) 125.75 136.04 125.73 116.21
CF (g/kg of DM) 63.76 63.63 62.11 62.06
Ash (g/kg of DM) 48.69 45.06 84.03 78.4
Oil (acid hydrolysis; %) 22.81 23.01 23.64 24.12
1Vitamin and mineral mix: 15 g/kg of DiCa P, 8 g/kg of limestone flour, 5 g/kg of salt, 2.5 g/kg of Cal–Mag, 80 g
of manganous oxide, 200 g of copper sulfate, 125 g of zinc oxide, 18 g of potassium iodate, 20 g of soduim
selenite (4.6%), 10 g of cobalt sulfate, 8 MIU/t of vitamin A, 2 MIU/t of vitamin D3, 15,000 IU/t of vitamin E.
2UFL = unite fourragere lait; unit of net energy, equivalent to 1 kg of standard air-dried barley
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Table 2: Fatty acid composition (g/100g) of the Palmit 80, Flax 30, LE-CLA and Fish
Oil supplements
g/100g of total fatty acids
Fatty Acid Palmit 80 Flax 30 LE-CLA Fish Oil
12:0 0.20 0.09 1.52 0.13
13:0 0.00 0.14 0.03 0.05
14:0 1.72 0.31 1.85 1.85
15:0 0.32 0.10 0.16 0.29
16:0 86.78 9.79 20.03 11.74
cis 16:1 0.24 0.13 0.15 1.52
17:0 0.00 0.08 0.17 0.00
18:0 1.69 3.32 19.47 3.49
18:1 cis-9 7.03 17.79 16.93 6.56
18:1 trans-9 0.14 0.43 0.33 2.28
18:1 trans-11 0.00 0.00 0.05 0.00
18:2 cis-9, cis-12 (n-6) 1.27 13.48 1.26 2.79
18:2 cis-9, trans-11 CLA (n-6) 0.00 0.08 14.51 0.21
18:2 trans-10, cis-12 CLA (n-6) 0.00 0.00 15.52 1.20
All trans 18:2 0.05 0.13 3.13 0.64
18:3 cis-6, cis-9, cis-12 (n-6) 0.21 0.17 0.00 0.00
18:3 cis-9, cis-12, cis-15 (n-3) 0.00 50.74 0.31 0.46
20:0 0.00 0.35 0.51 0.82
20:1 cis-11 0.00 0.32 0.08 2.54
20:2 cis-11, cis -14 0.00 0.03 0.00 0.33
20:3 cis-8, cis-11, cis-14 (n-6) 0.00 0.00 0.00 0.21
20:3 cis-11, cis-14, cis-17 (n-3) 0.00 0.06 0.00 1.15
20:4 (n-6) 0.00 0.00 0.00 0.44
20:5 EPA (n-3) 0.00 0.00 0.00 19.35
22:0 0.00 0.58 0.64 0.93
22:1 0.00 0.00 0.00 0.00
22:4 0.00 0.35 0.00 0.63
22:5 DPA (n-3) 0.00 0.00 0.00 6.73
22:6 DHA (n-3) 0.00 0.00 0.00 20.05
24:0 0.00 0.00 0.00 1.77
24:1 0.00 0.00 0.00 3.63
All < C18 89.26 10.65 23.92 15.57
All C18 10.40 86.15 71.51 17.63
All > C18 0.00 1.68 1.22 58.58
Total 99.66 98.51 96.66 92.47
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Table 3: Schedule of experimental procedures performed
1Between cow variation occurred in the number of days to ovulation after synchrony treatment and in
the length of the oestrous cycle, therefore exact day of dietary treatment varied for individual cows.
Day of dietary treatment1 Experimental procedure
0 Blood sample collected
5 Synchronisation protocol started
7 Blood sample collected
13 CIDR Removed
14-19 Cows observed for oestrus
14-35 Blood samples collected daily for a complete oestrous cycle.
Trans-rectal ultrasonography daily for a complete oestrous cycle
35-45 10 day rest period following first synchronised cycle
46 2 injections of PGF2α
46-52 Cows observed for oestrus
53-59 Liver and endometrial biopsies taken 7 days after ovulation
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Table 4: Bovine oligonucleotide primers used to detect endometrial and hepatic gene transcripts
Gene Name1 Sequence Accession Number
Product
Size
Endometrial tissue
PGFS2 F: 5'-TTCCCTTCAACCAGAGTTGG-3' M86544 113
R: 5'-TCCCTGGCTTCAGAGACACT-3'
PGFS1 F: 5'-TTTACAAGGAGCTGGGCTTC-3' NM_001040598 186
R: 5'-GCAGCAGCACTTTATCACCA-3'
FADS2 F: 5'-CAGCTCTGACTGGTGATGGA-3' NM_001083444 132
R: 5'-TCCCTATGGATCCAGTCTGC-3'
PTGS2 F: 5'-TTTGACCCAGAGCTGCTTTT-3' NM_174445 106
R: 5'-TCTGATCCTGGACCACTTCC-3'
PPARγ F: 5'-AGGATGGGGTCCTCATATCC-3' BC116098 121
R: 5'-GCGTTGAACTTCACAGCAAA-3'
PPARδ F: 5'-AGTACTGCCGCTTCCAGAAA-3' NM_001083636 131
R: 5'-GTTGTGCTGACTCCCCTCAT-3'
OTR F: 5'-TGGTTCTTGGTGGCTGTGTA-3' NM_174134 137
R: 5'-GCTTGGTTTGATGGTGGAGT-3'
CBR1 F: 5'-AAGAAATGCAGCCGTGAACT-3' NM_001034513 108
R: 5'-CACCCCGTTCTTTGTGTCTT-3'
PGES F: 5'-GGAACGCTGCCTCAGAGCCCA-3' NM_174443.2 101
R: 5'-CGACGAAGGGGTTCGGTCCG-3'
PLA2 F: 5'-TTCGAGCCATGGTAGGATTC-3' NM_001075864.1 148
R: 5'-GGCCCTTTCTCTGGAAAATC-3'
UBQ F: 5'-AGATCCAGGATAAGGAAGGCA-3' NM_174133 198
R: 5'-GCTCCACCTCCAGGGTGAT-3'
RSP9 F: 5'-CCTCGACCAAGAGCTGAAG-3' NM_001101152.1 64
R: 5'-CCTCCAGACCTCACGTTTGTTC-3'
Endometrial and hepatic tissue
PPARα F: 5'-TTGTGGCTGCTATCATTTGC-3' AF229356 135
R: 5'-AGAGGAAGACGTCGTCAGGA-3'
ACTB F: 5'-ACTTGCGCAGAAAACGAGAT-3' BT030480 123
R: 5'-CACCTTCACCGTTCCAGTTT-3'
Hepatic tissue
SLC27A1 F: 5'-ACTGTCTGCCCCTGTACCAC-3' NM_001033625.2 102
R: 5'-GGCTGGCTGAAAACTTCTTG-3'
ACADVL F: 5'-CACCATGAAAGGCATCATTG-3' NM_174494 160
R: 5'-GTTGGCACTCACCATGTACG-3'
ACOX1 F: 5'-AGCAAGAGAAATGGCTGCAT-3' NM_001035289 119
R: 5'-AGGGTCATAAGTGGCTGTGG-3'
CPT1A F: 5'-TCCTGGTGGGCTACCAATTA-3' FJ415874 181
R: 5'-TGCGTCTGTAAAGCAGGATG-3'
SREBF1 F: 5'-CCGAGGCCAAGTTGAATAAA-3' NM_001113302 136
R: 5'-TTCAGCGATTTGCTTTTGTG-3'
SCAP F: 5'-GGCTGATCCATGGTCACTTT-3' NM_001101889 183
R: 5'-AGTGGGTAGCAGCAGGCTAA-3'
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DGAT1 F: 5'-GCATCCTGAATTGGTGTGTG-3' NM_174693 158
R: 5'-CACAATGACCAGGCACAGAG-3'
GPAM1 F: 5'-ACGACGGAGGCTAGATGAGA-3' NM_001012282.1 140
R: 5'-TTCCACTTCTTGAGCGTGTG-3'
FABP1 F: 5'-GGAGTTCATGACTGGGGAGA-3' NM_175817 135
R: 5'-CCCTTCGTCATGGTACTGGT-3'
ACSL1 F: 5'-GGCATCTATCTCCACCCTGA-3' NM_001076085 145
R: 5'-CTCCCTCGCGTTAGACTTTG-3'
CYP2C F: 5'-TATGGACTCCTGCTCCTGCT-3' NM_001109792 177
R: 5'-CATACTGCTGGGGACAAGGT-3'
CYP3A F: 5'-GAAGCTGCAGGAGGAAATTG-3' Y10214 129
R: 5'-CTCCCAGCAATTGGAAACAT-3'
CAP1 F: 5'-AGGCGGTGACTTCAATGAGTTCCC-3' NM_001035010.1 121
R: 5'-ACAAGGAACCCAGTGGCACTTCG-3'
PSMD2 F: 5'-CTGTGGCTGGGCTGCTCACC-3' NM_001101197.1 183
R: 5'-CCACATCCACTGCCTGGCCC-3'
1PGFS; prostaglandin F synthase, FADS; fatty acid desaturase, PTGS; prostaglandin G/H synthase, PPAR; peroxisome
proliferator-activated receptor, OTR; oxytocin receptor, CBR; carbonyl reductase, PGES; prostaglandin E synthase, PLA;
Phospholipase UBQ; ubiquitin, ACTB; Beta-actin, RSP9; ribosomal protein S9, SLC27A1; solute carrier family 27, ACADVL;
Very long-chain specific acyl-CoA dehydrogenase, ACOX acyl-coenzyme A oxidase, CPT1A; carnitine palmitoyltransferase,
SREBF; sterol regulatory element binding transcription factor, SCAP; SREBF chaperone, DGAT; diacylglycerol O-
acyltransferase, GPAM; glycerol-3-phosphate acyltransferase, mitochondrial, FABP; fatty acid binding protein, ASCL; Long
chain fatty acid CoA ligase, CYP; cytochrome P450, CAP1; adenylate cyclase-associated protein, PSMD; proteasome 26S
subunit, non-ATPase.
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Table 5: Milk production, dry matter intake, energy balance and body condition score of cows
receiving Control, Flax, CLA and Fish Oil (FO) lipid supplements.
abcWithin row means not sharing a common superscript differ significantly (P < 0.05)
1Solids corrected milk yield = 12.3*milk fat yield + (6.56*(milk protein yield + milk lactose yield))-
(0.0752*milk yield)
Treatment P-value
Control Flax CLA FO SEM Trt Trt*time
Milk Yield (kg/d) 20.98a 21.64a 23.23b 21.11a 0.548 0.007 0.2
Milk Fat
% 4.33a 4.37a 2.94b 3.92c 0.098 <0.001 0.8
kg/d 0.93a 0.94a 0.67b 0.80c 0.027 <0.001 0.4
Milk Protein
% 3.09a 3.13a 2.95b 3.05ab 0.059 0.018 0.6
kg/d 0.64ac 0.69b 0.68ab 0.64c 0.015 0.03 0.13
Milk Lactose
% 4.65ab 4.67ac 4.60b 4.72c 0.026 0.008 0.6
kg/d 0.98a 1.01ab 1.05b 1.00ab 0.027 0.18 0.09
SCM yield (kg/d)1 20.72a 21.10a 17.88b 18.94b 0.492 <0.001 0.14
DMI (kg/d) 18.63 18.54 18.20 18.51 1.030 0.9 0.6
EBAL (UFL/d) 4.28 4.00 5.05 4.76 0.596 0.4 0.5
BCS 3.01 2.97 3.01 2.98 0.025 0.6 0.3
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Table 6: Ovarian follicular dynamics and peak plasma oestradiol concentrations in cows
receiving Control, Flax, CLA and Fish Oil (FO) lipid supplements.
Treatment
Control Flax CLA FO SEM P-value
Cycle Length 21.8a 18.3b 21.6ab 22.9a 1.21 0.09
Number of waves 2.30 2.40 2.17 2.43 0.202 0.8
Maximum diameter ovulatory
follicle (mm) 16.60 16.57 17.46 15.93 0.609 0.4
Peak plasma oestradiol at
synchronised oestrus (pg/ml) 4.01ab 5.33a 4.92ab 3.71b 0.543 0.15
Peak plasma oestradiol at
spontaneous oestrus (pg/ml) 3.41 4.26 4.24 3.53 0.390 0.2
Day of 1st wave emergence 0.9 0.8 1.0 1.6 0.30 0.3
1st wave day of peak follicle
diameter 7.5a 8.2ab 8.7ab 9.0b 0.63 0.2
Day of 2nd wave emergence 9.8 10.1 10.3 11.3 0.64 0.4
2nd wave day of peak follicle
diameter 18.0 18.8 18.8 20.4 1.01 0.4
Number of follicles in 1st wave 6.30a 5.40ab 5.63ab 4.13b 0.557 0.07
Number of follicles in 2nd wave 6.50 4.97 6.67 5.01 0.752 0.2
Maximum diameter follicle 1st
wave (mm) 16.17 16.82 15.75 14.83 0.796 0.4
Maximum diameter follicle 2nd
wave (mm) 15.83 16.26 15.98 15.01 0.861 0.7
Wave 1-2 emergence interval
(days) 8.9 9.3 9.3 10.0 0.58 0.6
Wave 1-2 peak interval (days) 10.4 10.3 10.2 10.9 1.25 1
abcWithin row means not sharing a common superscript differ significantly (P < 0.05)
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Table 7: Corpus luteum volume and plasma concentrations of progesterone, insulin, IGF-1, cholesterol and non-esterified fatty acids (NEFA) in cows
receiving Control, Flax, CLA and Fish Oil (FO) lipid supplements.1
Treatment P-value
Control Flax CLA FO SEM Trt Trt*time
Day 2 - 14
Progesterone (ng/ml) 5.13a 4.51b 5.38a 4.46b 0.321 0.013 0.9
CL Volume (mm3) 7352.3a 6821.1ab 7964.9a 5888.2b 509.29 0.04 0.8
Day 5-7
Progesterone (ng/ml) 3.96ab 3.47ab 4.24a 3.17b 0.34 0.15 0.4
CL Volume (mm3) 7287.2ab 6880.8ab 8125.7a 5618.6b 752.38 0.14 1
Day 8-14
Progesterone (ng/ml) 7.20ab 6.54a 7.74b 6.46a 0.426 0.014 0.9
CL Volume (mm3) 9490.2a 8588.5ab 9668.8 a 7353.7b 723.16 0.14 0.4
Day of Luteolysis 17.3 16.7 17.3 16.9 0.56 0.75 -
Insulin (µUI/mL) 4.41 (3.84 - 5.07)a 4.18 (3.65 - 4.79)ab 3.71 (3.19 - 4.32)ab 3.47 (2.96 - 4.07)b - 0.09 0.5
IGF-1 (ng/mL) 73.41 (64.29 - 83.83)a 89.13 (78.13 - 101.68)b 80.43 (70.50 - 91.76)ab 80.06 (69.92 - 91.68)ab - 0.07 0.9
Cholesterol (mmol/L) 4.97a 5.45ab 5.94b 5.19a 0.212 0.02 0.3
NEFA (mmol/L) 0.16 (0.13 - 0.19)a 0.21 (0.18 - 0.25)b 0.23 (0.19 - 0.28)b 0.24 (0.20 - 0.29)b - 0.01 0.8
a,b,cWithin row means not sharing the same superscript differ significantly (P < 0.05)
1Insulin, IGF-1 and NEFA values are back-trasnformed least-square means, followed by the 95 % confidence limits in parenthesis.
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Table 8: Endometrial and hepatic gene expression in cows receiving Control, Flax, CLA and
Fish Oil (FO) lipid supplements. 1,2
Treatment
Gene3 Control Flax CLA FO P value
Endometrial tissue
PPARα 0.78 (0.41 - 1.24) 0.93 (0.60 - 1.31) 0.67 (0.36 - 1.05) 0.87 (0.42 - 1.44) 0.8
PPARδ 0.55 (0.25 - 0.96)a 1.12 (0.74 - 1.59)b 0.74 (0.41 - 1.16)ab 1.07 (0.58 - 1.72)ab 0.085
PPARγ 1.33 (0.87 - 1.88)a 2.28 (1.71 - 2.94)bc 1.73 (1.24 - 2.30)ac 2.56 (1.81 - 3.43)b 0.015
PTGS2 0.97 (0.37 - 1.86)a 2.49 (1.62 - 3.54)b 1.62 (0.88 - 2.58)ab 1.03 (0.32 - 2.14)a 0.078
OTR 2.64 (1.57 - 3.91) 2.42 (1.57 - 3.40) 1.82 (1.02 - 2.79) 2.14 (1.02 -3.56) 0.4
PGFS1 0.82 (0.41 - 1.33) 0.79 (0.46 - 1.19) 0.71 (0.37 - 1.14) 0.96 (0.45 - 1.62) 0.8
PGFS2 0.87 (0.35 - 1.71) 1.72 (0.98 - 2.72) 1.00 (0.47 - 1.80) 1.86 (0.86 - 3.36) 0.13
PGES 1.37 (0.64 - 2.38) 1.65 (0.94 - 2.56) 1.72 (0.95 - 2.71) 2.07 (1.03 - 3.47) 0.7
CBR1 0.68 (0.32 - 1.20) 0.93 (0.58 -1.39) 0.61 (0.33 - 1.00) 1.12 (0.59 - 1.88) 0.4
PLA2 0.92 (0.38 – 1.68) 1.86 (1.19 – 2.68) 1.41 (0.79 – 2.21) 1.33 (0.57 – 2.42) 0.3
FADS2 1.31 (0.74 - 2.05) 1.82 (1.19 -2.58) 2.29 (1.59 - 3.13) 1.59 (0.85 -2.57) 0.3
Hepatic tissue
ACADVL 0.56 (0.36 - 0.78) 0.53 (0.36 - 0.71) 0.66 (0.46 - 0.87) 0.49 (0.27 - 0.73) 0.6
ACOX1 7.95 (7.50 - 8.37) 7.82 (7.46 - 8.16) 7.83 (7.44 - 8.21) 7.37 (6.85 - 7.86) 0.3
ACSL1 1.27 (0.98 - 1.56)a 1.25 (1.00 - 1.50)a 1.29 (1.02 - 0.89)a 0.57 (0.26 - 0.89)b 0.006
CPT1A 0.76 (0.46 - 1.11) 0.81 (0.55 - 1.11) 0.98 (0.67 - 1.32) 0.94 (0.56 - 1.35) 0.8
DGAT 1.81 (1.34 - 2.28) 1.74 (1.34 - 2.15) 2.00 (1.56 - 2.44) 1.74 (1.20 - 2.28) 0.6
FABP1 1.24 (0.85 - 1.67)a 1.57 (1.21 - 1.96)a 1.25 (0.88 - 1.66)a 0.42 (0.13 - 0.81)b 0.002
GPAM 1.91 (1.62 - 2.20) 1.75 (1.49 - 2.01) 1.98 (1.71 - 2.26) 1.72 (1.39 - 2.06) 0.5
SCAP 0.71 (0.39 - 1.08) 1.14 (0.82 - 1.49) 1.00 (0.66 - 1.37) 1.06 (0.64 - 1.52) 0.4
SLC27A1 1.19 (0.72 - 1.69) 1.55 (1.13 - 1.99) 1.59 (1.13 - 2.09) 1.73 (1.15 - 2.33) 0.4
SREBF1 1.46 (0.96 - 2.03)a 1.17 (0.77 - 1.63)a 1.50 (1.02 - 2.05)a 0.42 (0.10 - 0.88)b 0.01
PPARα 0.84 (0.57 - 1.13) 0.91 (0.67 - 1.16) 1.12 (0.84 - 1.41) 1.21 (0.87 - 1.56) 0.3
CYP3A 0.92 (0.58 - 1.30) 0.71 (0.44 - 1.02) 0.99 (0.66 - 1.35) 1.07 (0.66 - 1.53) 0.5
CYP2C 2.07 (1.48 - 2.68) 2.02 (1.51 - 2.54) 2.71 (2.14 - 3.30) 2.34 (1.65 - 3.05) 0.3
a,b,cWithin row means not sharing the same superscript differ significantly (P < 0.05)
1Gene expression values were normalized to the reference gene following adjustment for efficiencies and interplate variation
and converted to values relative to the highest cycle threshold (Ct) within each data set.
2Real-time reverse transcription-PCR values are back-transformed least squares means, followed by the 95% confidence limits
in parentheses
3PPAR; peroxisome proliferator-activated receptor, PTGS; prostaglandin G/H synthase, OTR; oxytocin receptor, PGFS;
prostaglandin F synthase, PGES; prostaglandin E synthase, CBR; carbonyl reductase, PLA; Phospholipase, FADS; fatty acid
desaturase. SLC27A1; solute carrier family 27, ACADVL; Very long-chain specific acyl-CoA dehydrogenase, ACOX acyl-
coenzyme A oxidase, ASCL; Long chain fatty acid CoA ligase, CPT1A; carnitine palmitoyltransferase, DGAT; diacylglycerol
O-acyltransferase, FABP; fatty acid binding protein, GPAM; glycerol-3-phosphate acyltransferase, mitochondrial, SREBF;
sterol regulatory element binding transcription factor, SCAP; SREBF chaperone, CYP; Cytochrome P450
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Figure 1: Plasma progesterone (upper panel) and corpus luteum volume (lower panel)
in cows receiving Control, Flax, CLA and Fish Oil (FO) lipid supplements. Statistical
analysis was performed using data from day 2 to day 14 following ovulation. Data
from day 15 to day 20 after ovulation are included for illustration purposes only. All
values are LSM
